Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 19;8(1):e000218. doi: 10.1136/jitc-2019-000218

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CD3xCD19 DART mediates lysis of primary CLL cells independent of IGHV mutation status, presence of TP53 aberrations or sensitivity to chemotherapy. (A–C) FACS analysis of lysis of CTV labeled primary CLL cocultured with healthy donor T cells in presence of CD3xCD19 DART. (A–B) Primary CLL cells cocultured in 1:1 (A) or 4:1 (B) E:T ratios and with different concentrations of the CD3xFITC and CD3xCD19 DART molecules for 24 hours and 4 days (n=3) (C) lysis of unmutated IGHV (n=5), mutated IGHV (n=4), chemorefractory (n=6) and TP53 mutated/17 p deleted (n=4) CLL by HD T cells in 4:1 E:T ratio after 4 days. CLL, chronic lymphocytic leukemia; CTV, cell trace violet; DART, dual affinity retargeting; HD, healthy donor; M-CLL, mutated IGHV; U-CLL, mutated IGHV.